Federal Register / Vol. 89, No. 229 / Wednesday, November 27, 2024 / Notices 93609 

AAQPS Advisory Committee members. 

All prepared remarks submitted on time 

will be considered as part of the 

meeting’s record. 

V. Submitting Written Comments 

Members of the public may submit 

written comments for consideration by 

the Committee at any time via email to 

AAQPS@cms.hhs.gov. Additionally, 

members of the public will have the 

opportunity to submit comments during 

the December 12, 2024, February 18, 

2025, and May 8, 2025, virtual meetings 

through the chat feature of the Zoom 

webinar platform. Members of the 

public are encouraged to submit lengthy 

written comments (more than three 

sentences) to the email address above. 

Advance submissions that become part 

of the committee deliberations will 

become part of the official record of the 

meeting. 

The Administrator of CMS, Chiquita 

Brooks-LaSure, having reviewed and 

approved this document, authorizes 

Vanessa Garcia, who is the Federal 

Register Liaison, to electronically sign 

this document for purposes of 

publication in the Federal Register. 

Vanessa Garcia, 

Federal Register Liaison, Centers for Medicare 

& Medicaid Services. 

[FR Doc. 2024–27740 Filed 11–26–24; 8:45 am] 

BILLING CODE 4120–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Food and Drug Administration 

[Docket No. FDA–2018–N–3236] 

Advisory Committee; Oncologic Drugs 

Advisory Committee; Renewal 

AGENCY: Food and Drug Administration, 

HHS. 

ACTION: Notice; renewal of Federal 

advisory committee. 

SUMMARY: The Food and Drug 

Administration (FDA or the Agency) is 

announcing the renewal of the 

Oncologic Drugs Advisory Committee 

by the Commissioner of Food and Drugs 

(the Commissioner). The Commissioner 

has determined that it is in the public 

interest to renew the Oncologic Drugs 

Advisory Committee for an additional 2 

years beyond the charter expiration 

date. The new charter will be in effect 

until the September 1, 2026, expiration 

date. 

DATES: Authority for the Oncologic 

Drugs Advisory Committee will expire 

on September 1, 2026, unless the 

Commissioner formally determines that 

renewal is in the public interest. 

FOR FURTHER INFORMATION CONTACT: 

Yvette Waples, Center for Drug 

Evaluation and Research, Food and 

Drug Administration, 10903 New 

Hampshire Ave., Bldg. 31, Rm. 2417, 

Silver Spring, MD 20993–0002, 301– 

796–9001, ODAC@fda.hhs.gov. 

SUPPLEMENTARY INFORMATION: Pursuant 

to 41 CFR 102–3.65 and approval by the 

Department of Health and Human 

Services and by the General Services 

Administration, FDA is announcing the 

renewal of the Oncologic Drugs 

Advisory Committee (the Committee). 

The Committee is a discretionary 

Federal advisory committee established 

to provide advice to the Commissioner. 

The Committee advises the 

Commissioner or designee in 

discharging responsibilities as they 

relate to helping to ensure safe and 

effective drugs for human use and, as 

required, any other product for which 

FDA has regulatory responsibility. 

The Committee reviews and evaluates 

data concerning the safety and 

effectiveness of marketed and 

investigational human drug products for 

use in the treatment of cancer and 

makes appropriate recommendations to 

the Commissioner. 

Pursuant to its charter, the Committee 

shall consist of a core of 13 voting 

members, including the Chair. Members 

and the Chair are selected by the 

Commissioner or designee from among 

authorities knowledgeable in the fields 

of general oncology, pediatric oncology, 

hematologic oncology, immunology 

oncology, biostatistics, and other related 

professions. Members will be invited to 

serve for overlapping terms of up to 4 

years. Non-Federal members of this 

committee will serve as Special 

Government Employees or 

representatives. Federal members will 

serve as Regular Government Employees 

or Ex-Officios. The core of voting 

members may include one technically 

qualified member, selected by the 

Commissioner or designee, who is 

identified with consumer interests and 

is recommended by either a consortium 

of consumer-oriented organizations or 

other interested persons. In addition to 

the voting members, the Committee may 

include one non-voting representative 

member who is identified with industry 

interests. There may also be an alternate 

industry representative. 

The Commissioner or designee shall 

have the authority to select members of 

other scientific and technical FDA 

advisory committees (normally not to 

exceed 10 members) to serve 

temporarily as voting members and to 

designate consultants to serve 

temporarily as voting members when: 

(1) expertise is required that is not 

available among current voting standing 

members of the Committee (when 

additional voting members are added to 

the Committee to provide needed 

expertise, a quorum will be based on the 

combined total of regular and added 

members) or (2) to comprise a quorum 

when, because of unforeseen 

circumstances, a quorum is or will be 

lacking. Because of the size of the 

Committee and the variety in the types 

of issues that it will consider, FDA may, 

in connection with a particular 

committee meeting, specify a quorum 

that is less than a majority of the current 

voting members. The Agency’s 

regulations (21 CFR 14.22(d)) authorize 

a committee charter to specify quorum 

requirements. 

If functioning as a medical device 

panel, an additional non-voting 

representative member of consumer 

interests and an additional non-voting 

representative member of industry 

interests will be included in addition to 

the voting members. 

Further information regarding the 

most recent charter and other 

information can be found at https://

www.fda.gov/advisory-committees/ 

oncologic-drugs-advisory-committee/ 

oncologic-drugs-advisory-committeeroster or by contacting the Designated 

Federal Officer (see FOR FURTHER

INFORMATION CONTACT). In light of the 

fact that no change has been made to the 

committee name or description of 

duties, no amendment will be made to 

21 CFR 14.100. 

This notice is issued under the 

Federal Advisory Committee Act as 

amended (5 U.S.C. 1001 et seq.). For 

general information related to FDA 

advisory committees, please visit us at 

http://www.fda.gov/ 

AdvisoryCommittees/default.htm. 

Dated: November 19, 2024. 

P. Ritu Nalubola, 

Associate Commissioner for Policy. 

[FR Doc. 2024–27797 Filed 11–26–24; 8:45 am] 

BILLING CODE 4164–01–P 


ddrumheller on DSK120RN23PROD with NOTICES1